Related by context. All words. (Click for frequent words.) 89 Phase 2b Clinical Trial 89 Completes Patient Enrollment 88 Phase IIb Trial 86 Drug Candidate 86 Completes Enrollment 86 Phase III Trial 85 Phase 2b Trial 85 Patient Enrollment 85 Clinical Trial Results 85 Receives Orphan Drug Designation 85 Pivotal Phase III 85 Pivotal Phase 85 Phase III Clinical Trial 85 Phase IIb Clinical Trial 85 Initiates Phase III 85 Investigational Compound 84 Initiates Phase II 84 Files IND 84 Initiates Clinical Trial 84 Demonstrates Positive 84 Novel Oral 84 Initiate Phase 84 Antitumor Activity 84 Study Evaluating 84 Initiates Enrollment 84 Phase 2a Trial 84 Trial Evaluating 83 Improves Survival 83 Phase 2a Clinical Trial 83 Oral Fingolimod 83 Presents Positive 83 Patients Treated With 83 Successfully Completes Phase 83 Study Showed 83 Initiates Clinical 83 NDA Submission 83 Submits NDA 83 Investigational Treatment 83 First Patient Enrolled 83 Demonstrates Significant 83 Adjuvant Treatment 83 Previously Treated 83 Prolongs Survival 82 FDA Approvals 82 JAK Inhibitor 82 Initiate Phase III 82 Initiates Phase 82 Granted Orphan Drug 82 Randomized Phase 82 Mylan Receives Approval 82 Preclinical Data 82 Pooled Analysis 82 Phase 2b Study 82 Combination REOLYSIN R 82 Tezampanel 82 Hormone Refractory Prostate Cancer 82 Clinical Trial Evaluating 82 Pivotal Study 82 Advanced Melanoma 81 First Patient Dosed 81 FDA Accepts 81 Presents Preclinical Data 81 Single Dose 81 Treated Patients 81 Survival Benefit 81 Achieves Primary Endpoint 81 Chronic Hepatitis C 81 Phase IIa Clinical Trial 81 PRN FDA Approves 81 Dose Escalation 81 Severe Sepsis 81 Generic Version 81 Milestone Payment 81 Well Tolerated 81 Shows Promising 80 Oral Calcitonin 80 Initiates Clinical Trials 80 Lupus Drug 80 Expanded Indication 80 Initiate Clinical Trial 80 Anti Tumor 80 Hsp# Inhibitor 80 Myeloma Patients 80 Patients Receiving 80 Drug Fails 80 Present Preclinical Data 80 Pivotal Trial 80 First Patient Treated 80 Improved Survival 80 Metastatic Colorectal Cancer 80 Renal Cell Carcinoma 80 Lung Cancer Drug 80 Commences Phase 80 Monotherapy 80 Is Well Tolerated 80 Begins Dosing 80 Newly Diagnosed Multiple Myeloma 80 Receives Approvable Letter 80 FDA Okays 80 IND Application 80 Patients Treated 80 Transdermal Patch 80 Combination Treatment 80 Demonstrated Significant 80 Peginterferon 80 Cholesterol Lowering Drug 80 Relapsing Multiple Sclerosis 80 Anti Tumor Activity 80 Confirmatory Phase 80 Shows Efficacy 80 FDA Clears 80 Statistically Significant 80 Fast Track Status 80 IND Filing 79 Refractory Hodgkin Lymphoma 79 Phase III Trials 79 Earns Milestone Payment 79 Gout Drug 79 Complicated Skin 79 Long Term Efficacy 79 Improves Outcomes 79 Phase 1b Clinical Trial 79 Mg Usa 79 Presents Preclinical 79 Drug Shows Promise 79 JAK2 Inhibitor 79 Demonstrates Efficacy 79 TO AVOID PREGNANCY WHILE 79 Schizophrenia Drug 79 Aflibercept 79 Migraine Drug 79 Rheumatoid Arthritis Drug 79 Hypertensive Patients 79 Prostate Cancer Vaccine 79 Significantly Improves 79 Dose Ranging Study 79 Osteoporosis Drug 79 Significantly Improved 79 Tyrosine Kinase Inhibitor 79 Adjunctive Therapy 79 Demonstrates Potent 79 Vicriviroc 79 II Clinical Trial 79 Investigational Agent 79 FDA APPROVES 79 Pulmonary Arterial Hypertension 79 Epilepsy Drug 79 Plaque Psoriasis 79 Elderly Patients 79 Metastatic Melanoma 79 HCV Protease Inhibitor 79 Medoxomil 79 Phase III Pivotal 79 Receives Orphan Drug 79 Safinamide 79 Lupus Nephritis 79 Preclinical Study 79 Diabetic Neuropathy 79 Investigational Drug 78 Milestone Payment From 78 Previously Untreated 78 Investigational Oral 78 HER2 Positive Breast Cancer 78 Relapsed Multiple Myeloma 78 Kinase Inhibitor 78 Rheumatoid Arthritis Patients 78 Novel Antibiotic 78 Blood Pressure Drug 78 Resistant Hypertension 78 Receives Fast Track 78 Initiates Phase 2b 78 Positive Opinion 78 R lenalidomide 78 Teva Provides Update 78 Efficacy Trial 78 Announces Tentative Approval 78 Treatment Naïve 78 Unfractionated Heparin 78 Disease Progression 78 PEGylated Fab fragment 78 Demonstrates Potential 78 Aliskiren 78 Pharmacokinetic Study 78 Anticancer Activity 78 Randomized Double blind 78 Initiates Dosing 78 Double Blind Placebo 78 Bosutinib 78 Advanced Colorectal Cancer 78 Protease Inhibitor 78 Oral Formulation 78 Pivotal Clinical Trial 78 Telaprevir VX 78 Arthritis Drug 78 SPRYCEL ® 78 Psoriasis Drug 78 Patients Enrolled 78 Controlled Trial 78 Peginterferon Alfa 2a 78 Cutaneous T 78 Receives Milestone Payment 78 Naive Patients 77 Disease Modifying 77 Treatment Naive Patients 77 Desvenlafaxine Succinate 77 oral prodrug 77 Patients Suffering 77 Brentuximab Vedotin SGN 77 Spectrum Pharmaceuticals Announces 77 Overactive Bladder 77 Vaccine Adjuvant 77 Demonstrates Sustained 77 Shows Promise Against 77 Acute Attacks 77 Subgroup Analysis 77 Intravenous Formulation 77 Novel Compound 77 Immunomedics Announces 77 Study Demonstrates 77 dasatinib Sprycel ® 77 Significantly Reduced 77 Collaborators Present 77 Low Dose 77 Dose Ranging 77 Prophylactic Treatment 77 Submits Biologics License Application 77 Generic Versions 77 Sapacitabine 77 Randomized Double Blind 77 Pafuramidine 77 MEK Inhibitor 77 Mg Uk 77 pralatrexate injection folate analogue 77 Demonstrate Significant 77 Reports Preclinical Data 77 Files Investigational 77 Relapsing Remitting Multiple Sclerosis 77 Testosterone Gel 77 Fungal Infections 77 Adjuvant Chemotherapy 77 Randomized Phase II 77 Infected Patients 77 Improve Survival 77 Glatiramer Acetate 77 RNAi Therapeutic 77 acetonide FA 77 Significantly Reduces 77 Commence Phase 77 Chronic Hepatitis B 77 vapreotide acetate 77 Prospective Randomized 77 Zorbtive TM 77 Taro Receives 77 Knee Osteoarthritis 77 erlotinib Tarceva R 77 Elagolix 76 Nicotine Vaccine 76 Aurora Kinase 76 Postmenopausal Osteoporosis 76 Combo Therapy 76 AAG geldanamycin analog 76 Phase III Clinical Trials 76 Combination Therapy 76 Relapsed Refractory 76 Dose Finding 76 Diabetic Foot Ulcer 76 Humanized Anti 76 Therapeutic Competitors Companies 76 Advanced Prostate Cancer 76 CCX# B 76 Proven Effective 76 Sangamo BioSciences Announces 76 Slow Progression 76 Benign Prostatic Hyperplasia 76 Glufosfamide 76 Pivotal Trials 76 Romidepsin 76 Submits Response 76 Mouse Model 76 Sirolimus Eluting 76 Pegloticase 76 Patent Covering 76 Mycophenolate Mofetil 76 Nilotinib 76 Topline Results 76 Vildagliptin 76 Shows Statistically Significant 76 Treatment Resistant 76 Drug Combo 76 Completes Dosing 76 Paclitaxel Carboplatin 76 Phase Ib Clinical Trial 76 dependent kinase inhibitor 76 Versus Placebo 76 Soft Tissue Sarcoma 76 Reveals Positive 76 BioSante Pharmaceuticals Announces 76 Million Milestone Payment 76 Heart Failure Patients 76 Vascular Disrupting Agent 76 Interferon Beta 76 Diabetic Nephropathy 76 HDAC Inhibitor 76 Plus Ribavirin 76 Eluting Stent 76 Oral Cladribine 76 developing Bicifadine serotonin 76 Melphalan 76 Recombinant Human 76 Receive Milestone Payment 76 Initiated Phase 76 Metastatic Prostate Cancer 76 Treatment Experienced 76 Acute Ischemic Stroke 76 Inhaled Corticosteroids 76 Systemic Delivery 76 Kidney Transplant Patients 76 Receives Positive Opinion 76 Second Pivotal Phase 76 Fondaparinux 76 Treatment Reduces 76 Adjuvant Therapy 76 Multiple Ascending Dose 76 Develop Novel 76 Postmenopausal Women 76 Efficacy Results 76 Receptor Agonist 76 Clinical Trial Data 76 Xcytrin R 76 Vaccine Candidate 76 Carboplatin Paclitaxel 76 Chronic Myeloid Leukemia 76 Enrolls First 76 Launches Generic Version 76 Anticancer Compound 76 Multiple Myeloma Patients 76 Golimumab 76 Treating Chronic 76 Parathyroid Hormone 76 Pharmacokinetics PK 76 Attenuates 76 Ecallantide 76 Announces Initiation 76 Biogen Genentech 76 Showed Significant 76 Clinical Outcome 76 Polymerase Inhibitor 76 Vitrasert R 76 VIVITROL ® 76 Demonstrates Statistically Significant 76 Crofelemer budesonide foam 76 CYT# potent vascular disrupting 76 Inhaled Insulin 76 TNF Tumor Necrosis Factor 76 Announces FDA Clearance 75 Intravitreal 75 Prostate Cancer Patients 75 Receives Complete Response 75 pan histone deacetylase 75 ISTODAX ® 75 R Saizen R 75 Orally Active 75 Chronic Sinusitis 75 FEMALES SHOULD BE ADVISED 75 Bone Metastases 75 Castration Resistant Prostate Cancer 75 Drug Prevents 75 Malignant Glioma 75 Sustained Reduction 75 Nucleoside 75 Treatment Shows Promise 75 Autologous Stem Cell Transplantation 75 RNAi Therapeutics 75 Monoclonal Antibody 75 Hydrochlorothiazide Tablets 75 Cholesterol Drug 75 Tiotropium 75 Novel Mechanism 75 Fixed Dose 75 Slows Progression 75 Secondary Hyperparathyroidism 75 Controlled Study 75 Lowers Risk 75 Atypical Hemolytic Uremic Syndrome 75 Paliperidone Palmitate 75 Lung Cancer Trial 75 Novel Inhibitor 75 Renal Cancer 75 beta 1a 75 PEGINTRON TM 75 Tolerability 75 Personalized Immunotherapy 75 Gets FDA Clearance 75 investigational oral inhibitor 75 Myelodysplastic Syndrome MDS 75 Orphan Status 75 Pediatric Patients 75 Inhalation Solution 75 Epratuzumab 75 Romiplostim 75 Sagent Pharmaceuticals Announces 75 ACE Inhibitors 75 Rotavirus Vaccine 75 Maribavir 75 Receptor Antagonist 75 Aztreonam Lysine 75 pan HDAC inhibitor 75 Tumor Growth 75 Patients Undergoing 75 Cypher Sirolimus 75 ® lenalidomide 75 virus HCV protease inhibitor 75 Premenopausal Women 75 Hormone Receptor Positive 75 LymphoStat B belimumab 75 Oral Mucositis 75 Phase IIa Trial 75 alfa 2a 75 Effectively Treats 75 INTEGRILIN R 75 Multicenter Randomized 75 Clinical Study Shows 75 Patient Enrolment 75 Ozarelix 75 Breast Cancer Recurrence 75 Ranolazine 75 Primary Hypercholesterolemia 75 Ovitrelle R Serostim 75 CYP#A# CYP#D# 75 Interferon Gamma 75 induced macular edema 75 Tipranavir 75 ACTEMRA TM 75 Alvine Pharmaceuticals 75 PDUFA Date 75 FOLOTYN ® 75 Seasonal Allergic Rhinitis 75 Levels Linked 75 Bevacizumab 75 Anticancer Drug 75 Generic Version Of 75 Phase III Pivotal Trial 75 Potent Antiviral Activity 75 Completes Patient Enrolment 75 Fewer Side Effects 74 Metastatic Renal Cell Carcinoma 74 topical gel formulation 74 Therapy Improves 74 Initiate Phase II 74 Bipolar Depression 74 Pivotal Phase II 74 Extended Release 74 Milestone Payments 74 ST Elevation Myocardial 74 NICE Recommends 74 Osteoporosis Treatment 74 Interferon beta 1a 74 FDA Clearance 74 Supplemental Biologics License Application 74 Onyx Pharmaceuticals Announces 74 Announces Poster Presentations 74 Pemetrexed 74 Fracture Risk 74 Synta Announces 74 Hypercholesterolemia 74 interferon beta 1a infertility 74 evaluating tivozanib 74 Receives FDA Clearance 74 TRANSDUR ™ 74 Presents Positive Preclinical 74 PEGylated anti 74 Kuvan R 74 MKC# 74 Xeloda ® 74 Antiviral Activity 74 Data Suggest 74 Myelodysplastic Syndromes 74 Pegylated 74 Efficacious 74 Partial Onset Seizures 74 TRANSDUR ® 74 ALN HPN 74 ABLYNX 74 Gene Variant 74 Varespladib 74 Hematological Malignancies 74 Hepatitis C Patients 74 sapropterin dihydrochloride 74 Advanced Renal Cell 74 Phase 2a Study 74 Aeolus Pharmaceuticals Announces 74 Capsules CII 74 Randomized Clinical Trial 74 Diabetic Patients 74 Platelet Inhibition 74 IN PATIENTS WITH 74 Anemia Drug 74 Proves Effective 74 Randomized Study 74 cetuximab Erbitux R 74 Preclinical Models 74 Lanthanum Carbonate 74 Allergic Rhinitis 74 Predict Risk 74 Lung Cancer Patients 74 Appears Safe 74 delivers fluocinolone acetonide FA 74 Posaconazole 74 myelodysplastic myeloproliferative diseases 74 Nebulized 74 PHASE III 74 Bortezomib 74 Submits IND 74 Reduces Risk 74 Insulin Glargine 74 lexidronam injection 74 Irinotecan 74 methylnaltrexone bromide 74 Dasatinib 74 Node Positive 74 FDA Approves 74 Vidaza ® 74 Peginterferon alfa 2b 74 Osteoporosis Drugs 74 Recurrent Glioblastoma 74 Announce License Agreement 74 Anthracycline 74 Telik Announces 74 Immunotherapeutic 74 Artery Disease 74 Diamyd Medical Diamyd 74 Novel Therapeutic 74 Antigen Specific 74 Therapeutic Vaccine 74 Shows Promise 74 Commercialize Novel 74 TKB# 74 selective A2A adenosine receptor 74 Novel Anti Inflammatory 74 Inhalation Aerosol 74 Bivalirudin 74 Clinical Efficacy 74 Flamel Technologies Announces 74 FS Antihemophilic Factor Recombinant 74 Antibody Drug Conjugate 74 Metabolic Disorder 74 Oral Laquinimod 74 MKC# MT 74 refractory chronic lymphocytic 74 Regeneron Pharma 74 Cocaine Addiction 74 Schizophrenia Treatment 74 orally inhaled migraine 74 Eszopiclone 74 Inhaled Nitric Oxide 74 carcinoma mCRC 74 abacavir sulfate lamivudine 74 Placebo Controlled Trial 74 Regenerative Cells 74 Blood Thinner 74 See CLINICAL PHARMACOLOGY 74 Successfully Treated 74 Hepatitis C Genotype 74 diarrhea fatigue asthenia 74 Renal Impairment 74 BCG refractory carcinoma 74 diarrhea predominant irritable 74 TNF Blockers 74 brand ciclesonide HFA 73 Stent Restenosis 73 Anticancer Agent 73 VIVUS Announces 73 By JENNIFER LEARN 73 Decitabine 73 Therapy Reduces 73 Bare Metal Stents 73 Lung Cancer Survival 73 humanized interleukin 6 73 GATTEX TM 73 Beta Blocker 73 Syncria R 73 Licenses Novel 73 Hospital Acquired Pneumonia 73 5 Fluorouracil 73 Telbivudine 73 IMiDs ® 73 Statin Therapy 73 Placebo Controlled Study 73 novel orally inhaled 73 J Am Coll 73 Bazedoxifene 73 Hepatic Encephalopathy 73 Recurrent Breast Cancer 73 Capecitabine 73 Gene Linked 73 Ridaforolimus 73 Degarelix 73 Pegylated Liposomal Doxorubicin 73 Therapeutic Antibody 73 Diabetic Neuropathic Pain 73 Bucindolol 73 Synthetic Peptide 73 Anti Clotting Drug 73 Biomarker Study 73 adalimumab Humira 73 Atripla combines 73 Albuferon TM 73 Prodrug 73 Oral Interferon 73 Myelofibrosis 73 R roscovitine CDK cyclin 73 Methylnaltrexone 73 Poniard Pharmaceuticals Announces 73 Atypical Antipsychotic 73 HER2 Positive 73 Stent Implantation 73 Enlarged Prostate 73 IIa Clinical Trial 73 Hematological Cancers 73 IL# PE#QQR 73 5 FU leucovorin 73 Treatment Regimen 73 Omacetaxine 73 non nucleoside inhibitor 73 Long Term Survival 73 catheter occlusion 73 Malignant Melanoma 73 Rigel R# 73 Increased Mortality 73 Sustained Efficacy 73 Study Shows Promise 73 Cethromycin 73 Statin Drugs 73 Multicenter Phase 73 Sirolimus Eluting Stent 73 Submits Supplemental 73 bone marrow reticulin deposition 73 Advanced Ovarian Cancer 73 Newly Diagnosed Patients 73 induce orthostatic hypotension 73 rasagiline tablets 73 Lubiprostone 73 Inflammatory Markers 73 Febuxostat 73 Reduces Pain 73 Zoledronic Acid 73 Optimer Pharma 73 Treatment Naïve Patients 73 MKC# MKC# PP 73 hyperphenylalaninemia HPA due 73 Chronic Constipation 73 R memantine HCl 73 Archexin 73 orally administered inhibitor 73 Confirms Efficacy 73 Phospholipase A2 73 Chemotherapy Induced 73 Sustained Release 73 Azacitidine 73 Dupuytren Contracture 73 Anti CD# Antibody 73 Randomized Trials 73 PROCTOCORT R 73 Colorectal Cancer Patients 73 dextromethorphan quinidine 73 Microplasmin 73 Announcement acc 73 oral nucleoside analogue 73 Pegylated Interferon 73 PKC# 73 Abiraterone Acetate 73 Serostim ® 73 Kidney Function 73 Tumor Targeting 73 Copegus ® 73 Sandostatin R 73 Gentium Announces 73 Pazopanib 73 STELARA TM 73 AVONEX ® 73 Randomized Clinical Trials 73 C1 Inhibitor 73 mGluR2 positive 73 Systemic Sclerosis 73 Randomized Phase III 73 novel VDA molecule 73 Diabetic Macular Edema 73 Tesamorelin 73 markets COLAZAL 73 COLAZAL ® 73 albiglutide 73 Nitazoxanide 73 Drug Coated Stent 73 Poorly Controlled 73 Valsartan 73 Inhibits 73 RANK Ligand inhibitor 73 Cholesterol Drugs 73 Chronic Heart Failure 73 Tigecycline 73 Therapeutic Potential 73 Antithrombin 73 Vaginal Gel 73 Acute Heart Failure 73 Gastric Cancer 73 J Am Acad 73 vinorelbine tartrate 73 Namenda ® 73 Fulvestrant 73 Small Molecule 73 Panzem R 73 XL# anticancer compounds 73 metaglidasen 73 Paraplatin ® 73 benzoic acid hyoscyamine sulfate 73 dual endothelin receptor antagonist 73 Bone Fracture 73 Sevelamer 73 Double Blind Randomized 73 FUSILEV enhances 73 targeted radiotherapeutic 73 REG1 Anticoagulation System 73 Perifosine KRX 73 Hemodialysis Patients 73 Oral Spray 73 ® decitabine 73 CysDisplay R 73 Antitumor 73 Replacement Therapy 73 Anti Inflammatory Drug 73 Fludarabine 73 Vaccine Protects Against 73 LibiGel ® 73 dihydrochloride Tablets 73 Placebo Controlled 72 Tocilizumab 72 Antiangiogenic 72 Interferon Alpha 72 Granulocyte Colony Stimulating Factor 72 SABER ™ 72 Novel Treatments 72 NMT Medical Announces 72 J Allergy Clin 72 metastatic malignant 72 BUPHENYL R sodium phenylbutyrate 72 Dendritic Cells 72 Maleate 72 sunitinib Sutent ® 72 Minimally Invasive Treatment 72 Bucindolol Based 72 Telik logo TELINTRA 72 Testosterone Patch 72 Neoadjuvant 72 Therapeutic Efficacy 72 Angiotensin Converting Enzyme 72 DOR BioPharma Announces 72 Ischemic 72 Kidney Transplant Recipients 72 Ofatumumab 72 Enoxaparin 72 erlotinib Tarceva ® 72 Agonist MABA program 72 Patient Treated 72 Epidermal Growth Factor Receptor 72 Dementia Related Psychosis 72 Cites Positive 72 evaluating picoplatin 72 BARACLUDE R 72 Neoadjuvant Chemotherapy 72 aripiprazole Abilify 72 Elotuzumab 72 Acetate Rectal Suppositories 72 J Clin 72 Advanced Pancreatic Cancer 72 Remission Maintenance 72 Proc Am Soc 72 Receives SFDA Approval 72 Increases Risk 72 FOLFOX6 chemotherapy regimen 72 balsalazide disodium Capsules 72 Cardiotoxicity 72 investigational humanized monoclonal antibody 72 Etanercept 72 Obese Patients 72 Civacir 72 GW# [003] 72 Gemzar ® 72 Brain Metastases 72 mGluR5 NAM 72 Unstable Angina Non 72 ZOLINZA 72 relapsed MM 72 Sunesis Pharma 72 STERIS Corporation Announces 72 Oral Insulin 72 Lamotrigine 72 Abstract Accepted 72 Diffuse Large B 72 Daclizumab 72 candidates Azedra TM 72 MAGE A3 ASCI 72 INSPIRE Trial Phase III 72 ANDA Filing 72 Testosterone MDTS R 72 Renal Anemia 72 Toremifene 72 phenyl salicylate methylene blue 72 Erectile Dysfunction Drug 72 Bipolar Mania 72 ELADUR TM 72 Gene Variation 72 Vidaza R 72 Unresectable 72 2 methoxyestradiol 72 COPEGUS R 72 Preclinical Efficacy 72 familial amyloidotic polyneuropathy FAP 72 Drug Resistant 72 Eculizumab 72 5 fluorouracil leucovorin 72 Nuvelo Announces 72 Oral Anticoagulant 72 CYPHER R Sirolimus Eluting 72 Fluticasone 72 Fluconazole 72 Ziprasidone 72 Potentially Fatal 72 FDA Approves Drug 72 Successfully Treats 72 R metformin Concor 72 Treat Anemia 72 Neovascular Age Related Macular 72 Non Responders 72 ODT metoclopramide HCl PEPCID 72 Limb Ischemia 72 bevacizumab Avastin R 72 Hepatocellular Carcinoma 72 AVAPRO 72 NASH Huntington 72 mGluR5 negative 72 KRN# 72 Progressive Multifocal Leukoencephalopathy 72 Immunomodulatory 72 R bisoprolol Euthyrox 72 personalized cellular immunotherapy 72 Randomized Double Blind Placebo 72 Anticoagulant 72 Invasive Fungal Infections 72 INDUSTRY ASSESSMENTS 72 Anti Angiogenic 72 Venous Thromboembolism 72 Bepreve TM 72 Stomach Cancer 72 Camptosar ® 72 Peginterferon Alfa 2b 72 Announce Initiation 72 Cyclophosphamide 72 Experimental Vaccine 72 Ustekinumab 72 Gene Variants 72 LymphoStat B TM 72 Gastrointestinal Stromal Tumors 72 Cell Transplants 72 initiated Phase Ib 72 Hedgehog Pathway 72 Antidepressant Drug 72 Voreloxin 72 AVASTIN 72 Premature Infants 72 Visceral Fat 72 candesartan cilexetil 72 Molecular Diagnostic Test 72 Palifosfamide 72 NOTE POSIDUR ™ 72 Refractory Angina 72 Silodosin 72 Telithromycin 72 Breast Cancer Cells 72 Gene Mutation 72 Testosterone MDTS ® 72 Namenda Memantine HCl 72 Wafer polifeprosan 72 docetaxel Taxotere ® 72 Pharmacyclics Announces 72 FDA Panel Recommends 72 Non Invasive Treatment 72 Boceprevir 72 ergot derivatives 72 Enzyme Replacement Therapy 72 novel nucleoside analog 72 Atypical Antipsychotics 72 Heartburn Drugs 72 Zoloft sertraline 72 Lenalidomide 72 Weight Loss Drug 72 Clinical Evaluation 72 Tumor Response 72 Skeletal Muscle 72 Topical Treatment 72 Ambrisentan 72 Anticancer Drugs 72 Pirfenidone 72 FOLFOX6 72 Ropinirole 72 markets HP Acthar 72 imatinib Gleevec ® 72 Multicenter Trial 72 Metformin HCl 72 Iloperidone 72 HIV treatments Reyataz 72 TELINTRA R 72 liposomal formulation 72 Reduced Risk 72 selective modulator 72 essential thrombocythemia ET 72 Left Ventricular 72 Epoetin Alfa 72 oral proteasome inhibitor 72 Seasonal Influenza Vaccine 72 novel emulsion formulation 72 Universal Flu Vaccine 72 Chronic Lymphocytic Leukemia 72 Thiazolidinediones 72 Shingles Vaccine 72 Levoleucovorin 72 Panzem R NCD 72 Factor Receptor 72 Hepatitis C Treatment 72 Temsirolimus 72 Lenocta TM 72 Diuretic 72 Frozen Shoulder syndrome Adhesive 72 Genes Predict 72 AVI BioPharma Announces 72 Orally administered 72 Announces Presentation 72 oral dual endothelin 72 Gel repository corticotropin injection 72 Cholesterol Lowering 72 sapropterin dihydrochloride Tablets 72 Critically Ill Patients 72 Inflammatory Arthritis 72 Antipsychotic 72 TRANSFORMS 72 Carotid Stenting 72 Glucose Control 72 TLK# 72 Liver Injury 72 Tablet Formulation 72 Desvenlafaxine 72 Disease IBD 72 Fludara ® 72 Announces Publication 72 LENALIDOMIDE 72 recurrent metastatic ovarian cancer 72 Protease Inhibitors 72 toenail onychomycosis 71 Adefovir 71 Protein Linked 71 interferon gamma 1b 71 Adalimumab 71 Grants Orphan Drug 71 Metabolic Efficiency 71 Severe Asthma 71 Belimumab 71 Tesetaxel 71 5q MDS 71 combines bupropion 71 mitoxantrone plus 71 metastatic castration resistant 71 Prove Effective 71 ARIXTRA R 71 Late Breaker 71 Hyperlipidemia 71 Liposomal 71 acute peripheral arterial 71 sorafenib tablets 71 Randomised Trial 71 Ceflatonin R 71 candidates Azedra 71 Microwave Ablation System 71 thalidomide Thalomid 71 PEGylated interferon beta 1a 71 Chemoradiation 71 adenosine injection 71 Improves Quality 71 VentiRx Pharmaceuticals 71 Non Inferiority 71 Daptomycin 71 Novel Compounds 71 Meta Analysis 71 Crit Rev 71 By JAMAAL ABDUL 71 chronic eosinophilic leukemia 71 Effective Than 71 Chronic Renal Failure 71 Adjunctive 71 Acute Exacerbations 71 Clinically Significant